SCHEMBL5617029

SCHEMBL5617029

CCOCc1nc2cnc3ccccc3c2n1CCCC(=O)N1CCOCC1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HPGD P15428 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
SIRT3 Q9NTG7 1/20 0.40
TLR7 Q9NYK1 1/20 0.39
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
POLB P06746 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
TLR8 Q9NR97 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5617132 0.97 HPGD (0.45) LMNANPSR1TDP1HPGDMEN1
SCHEMBL5616913 0.95 NPSR1 (0.42) LMNANPSR1TDP1MEN1KMT2A
SCHEMBL5617289 0.88 ALDH1A1 (0.41) LMNATDP1HPGDKDM4ECYP1A2
SCHEMBL5617028 0.86 HPGD (0.45) LMNANPSR1TDP1HPGDMEN1
SCHEMBL5617245 0.85 HPGD (0.47) LMNANPSR1TDP1HPGDSIRT3
SCHEMBL5616923 0.85 ALDH1A1 (0.41) LMNATDP1HPGDKDM4ECYP1A2
SCHEMBL5617061 0.84 TLR8 (0.58) TLR7TLR8
SCHEMBL5616927 0.84 TLR8 (0.46) HPGDMEN1KMT2ATLR7KDM4E
SCHEMBL5616910 0.83 MEN1 (0.47) NPSR1TDP1HPGDMEN1KMT2A
SCHEMBL5616939 0.83 MEN1 (0.46) NPSR1TDP1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8697873-B2 Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-04-15 US disclosed
US-20070219196-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2007-09-20 US disclosed
EP-1730143-A2 AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES 3M Innovative Properties Company (US) 2006-12-13 EP disclosed
WO-2005094531-A2 AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219196-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES IL2, IL4, IFNG LMNA 4342/4885NPSR1 3855/4885TDP1 2878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.